**Draft Guidance on Propranolol Hydrochloride**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Propranolol hydrochloride

**Dosage Form: Route:** Extended release capsule; oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 160 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population  
   **Additional comments:** None

2. **Type of study:** Fed  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 160 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population  
   **Additional comments:** None

**Analytes to measure:** Propranolol and its active metabolite, 4-hydroxypropranolol, in plasma using an achiral assay

Submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for area under the curve and maximum concentration.

**Bioequivalence based on (90% CI):** Propranolol

**Additional strengths:** Bioequivalence of the 60 mg, 80 mg, and 120 mg strengths to the corresponding reference product strengths may be demonstrated based on principles laid out in the FDA guidance on *Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA.*
**Dissolution test method and sampling times:**
For modified release drug products, applicants should develop specific discriminating dissolution methods. Alternatively, applicants may use the dissolution method set forth in any related official United States Pharmacopeia (USP) drug product monograph or in the FDA’s database, [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/), provided that applicants submit adequate dissolution data supporting the discriminating ability of such a method. If a new dissolution method is developed, submit the dissolution method development and validation report with the complete information/data supporting the proposed method. Conduct comparative dissolution testing on 12 dosage units for each strength of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

In addition to the method above, submit dissolution profiles on 12 dosage units for each strength of the test and reference products generated using USP Apparatus 1 at 100 rpm and/or Apparatus 2 at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer). Agitation speeds may be increased if appropriate. It is acceptable to add a small amount of surfactant if necessary. Include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released to provide assurance against premature release of drug (dose dumping) from the formulation.